NMC Health Plc
NMC:LN

Dr B.R. Shetty is the Executive Vice-Chairman & CEO of NMC Healthcare Born in India, Dr Shetty arrived in the UAE in 1973 shortly after the country’s formation. As a trained pharmacist, he opened his first pharmacy in 1975. In 1975 he established the New Medical Centre (NMC), which also included a dedicated dental department. NMC has since grown to become the UAE’s largest private sector healthcare provider. Today, it has hospitals and clinics across the UAE and treats almost two million patients a year. Dr Shetty’s other business activities include UAE Exchange, a leading global money transfer and foreign exchange provider, of which he is Managing Director and CEO, and investments in hospitality, food and beverage, pharmaceutical manufacturing and real estate. Dr Shetty received the Order of Abu Dhabi in 2005, the country’s highest civilian award, for contribution to the development of the community and the cause of the emirate, as well as the Padma Shri Award from the government of India in January 2009. In addition to his business activities, Dr Shetty is involved in several philanthropic causes. He has supported the development of a medical institution in the north Indian state of Uttaranchal and is the founder and patron of the Indian Pharmaceutical Association in the UAE. He is a member of the Advisory Board of the Dubai Economic Department’s Financial Sector, Chairman of the Abu Dhabi Indian School, Founder and Vice President of the Swiss Business Council, and Founder of the Australian Business Council, the Canadian Business Council, the Netherlands Business Group and the Philippines Business Council. Dr Shetty is also a member of the Executive Panel of Dubai’s Pharmaceutical and Health Equipment Trading Business Group under the Dubai Chamber of Commerce and Industry A passionate cricket fan, Dr Shetty is the former President of the Abu Dhabi Cricket Council and was the Managing Director of the Abu Dhabi Cricket Club from its inception in 1989 until 2006 Dr B. R. Shetty received a Doctorate from Georgia State University, Atlanta, USA and was invited by the Harvard Business School to attend its Owner/President Management programme. He is also a member of the International Advisory Board of Boston University, USA.

Mr Tompkins was Non-Executive Chairman of Allied Healthcare International Inc. one of the UK’s leading providers of domiciliary care and healthcare staffing services, from 2007 to 2009, serving as a Director from 2005 to 2009. From 2005 to 2008 he also served as Non-Executive Chairman of Healthcare Enterprise Group Plc, an international healthcare products company which was listed on the AIM market in London. Mr Tompkins served as Conseiller Special aupres du Conseil D’Administration of Sodexo S.A. from November 2010 to August 2012 after serving as a Non-Executive Director from 2002 to 2010 and a member of its Audit Committee for six of those eight years. Other previous directorships have included Abbey Healthcare Group Inc., and Apria Healthcare Group Inc. Prior to his nonexecutive director roles, Mr Tompkins served as the Chief Executive Office of Compagnie Financiere Haussmann, a publicly listed company in France involved in property development, investment and management. Mr Tompkins began his career in investment banking in 1964 with Samuel Montagu & Company (now HSBC). From 1965 to 1971, he was a Management Consultant with Booz Allen Hamilton, Inc., working on assignments in the UK, continental Europe and the U.S. Mr Tompkins returned to investment banking joining Slater Walker Securities group from 1972 to 1974. He subsequently entered into international real-estate development from 1974 to 1987 investing in both residential and commercial assets across the Middle East, the United States and Europe. Since 1987, he has been focussed on financing small and medium sized enterprises whilst also contributing at board level of a number of listed companies.

Mr Bomford is a qualified Chartered Accountant who spent 24 years with Ernst & Young in a number of roles in the Middle East and East Africa including Abu Dhabi, Riyadh, Dubai and Jeddah. For his last 15 years with Ernst & Young, he was a partner with a number of international clients across a range of sectors including healthcare, oil, banking and construction. In 2000, Mr Bomford retired from Ernst & Young and since then has undertaken a number of roles including a Board Member of an Agricultural Trust funding agricultural projects and an Official Mentor providing Business Advice and Services to clients of the Prince’s Trust. Given his strong financial expertise, Mr Bomford was appointed as Chairman of the Audit Committee upon his appointment to the Board.

Mrs Lawrence has over 20 years’ experience as a Chief Executive Officer in the hospital and healthcare sector. From 2000 to July 2012 she served as CEO of the Chelsea and Westminster Hospital, which gained NHS Foundation Trust status in 2006. Prior to 2000 she served as CEO of North Hertfordshire NHS trust from 1996 to 2000 and Hounslow and Spelthorne Community and Mental Health Trust from 1989 to 1996. Mrs Lawrence chaired the UK-wide negotiations for the Staff and Associate Specialists (SAS) Doctors contract during 2004 to 2006 and chaired the “Agenda for Change” three-year pay deal for non-medical staff on behalf of NHS employers during 2006 to 2009. She has also served as a Commissioner for the UK Prime Minister’s Commission for the Future of Nursing and Midwifery and was a Founding Member of the Dr Foster Global Comparators Founders Board, which is an initiative to share comparative health data with other leading medical institutions in various countries to improve clinical quality. Mrs Lawrence originally trained as a nurse at St Mary’s Hospital Paddington and is a Chartered Fellow of the Institute of Personnel Management. She was appointed, by Secretary of State for Health, as a Non-Executive Director of Monitor, the NHS Regulator, in July 2012. Mrs Lawrence was awarded an OBE in the 2010 New Year Honours List for her services to healthcare.

Lord Clanwilliam is an international businessman and high-level government and financial communications specialist possessing over 30 years of business and political experience across a broad range of sectors, including mining, drilling, oilfield services and operational management and consultancy. During his career, Lord Clanwilliam has established an extensive network of senior level governmental and institutional contacts across the Middle East, the United Kingdom and Eastern Europe. He is currently Chairman of Eurasia Drilling Company, a drilling and work-over company operating in Eurasia and listed on the Premium Segment of the London Stock Exchange. He is also a Non-Executive Director of Polyus Gold OJSC, a Russian gold mining company listed on the Premium Segment of the London Stock Exchange. Lord Clanwilliam is the Founding Partner and Chairman of Gardant Communications Limited, a political, strategic, financial and litigation communications company based in London and Senior Advisor to Milio International Limited, a British owned and operated commodities and logistics company. Lord Clanwilliam graduated from Eton College in 1978 and from The Royal Military Academy, Sandhurst in 1979 after which he served for four years with the 1st Battalion Coldstream Guards.

Mr Basaddiq is a fellow of the Institute of Chartered Accountants in England & Wales (FCA) and a licensed auditor and consultant in the UAE. He trained and qualified as a chartered accountant with Ernst & Young, London and spent over 25 years with Ernst & Young in the UK and the GCC, 15 of those as an equity partner. During his period at EY, Abdulrahman served as the Managing Partner of their Riyadh and Abu Dhabi offices, in addition to responsibilities as UAE Country partner in charge. During his tenure in Riyadh, he oversaw the development and implementation of the only Saudisation program within the profession in the Kingdom at the time. He also served as an elected member of the firm’s executive committee for some eight years, in addition to serving on the human resources committee for a number of years. Mr Basaddiq spent over 12 years with a number of Gulf based diversified groups across multiple jurisdictions and sectors including healthcare, global public and private equities, venture capital, real estate investment, development and construction, steel trading and fabrication, in addition to food manufacturing, retail and packaging. He also spent over five years serving on two audit committees, chairing one of them, in addition to oversight responsibilities in the development of audit committees and the related internal audit functions of other entities, which have grown in size and complexity, to comply with the ever increasing governance and other regulatory demands.

Mrs Salma Hareb, is the CEO of Economic Zones World and spearheads innovative product development to provide greater value to EZW customers. She has been instrumental in the creation of the Dubai Logistics Corridor, which quadruples Dubai’s logistics efficiencies. Under her leadership, Jebel Ali Free Zone (Jafza), the flagship Free Zone of Economic Zones World, has been recognized as one of the most efficient Free Zones in the World, with a customer base of more than 7,300 companies, and 120 of the Global Fortune 500 enterprises, with total non-oil trade of US$90.2 billion, contributing more than 20 percent to Dubai’s GDP. As head of Economic Zones World, she also leads Technopark, the company’s research and development initiative in core economic sectors including Water, Health, Energy, Engineering, e-Commerce and Logistics, as well as Dubai Auto Zone (DAZ), a comprehensive market place for the Auto Industry catering to buyers, sellers, service providers, principals and traders. Internationally, she is actively overseeing Economic Zones World’s development of a logistics park in South Carolina, USA, Special Economic Zones in India, and a Free Zone in Djibouti, Africa. Prior to her role as CEO, she worked as Jafza’s Chief Planning Officer, responsible for strategic planning, business development, finance, and human resources. Before that she worked as Chief Haematologist in the Department of Health and Medical Services. She completed her education in the UAE and the UK, in the fields of Medical Sciences, Information Technology and Business in addition to a one year post graduate study in Haematology at the University of Cardiff. Mrs Salma Hareb’s distinctive initiatives and achievements have been recognised with several awards over the years. Most recently, she received the Frost & Sullivan Growth, Innovation and Leadership Award 2014, and last year, she was named the “Overall Winner – Professional Category” in Emirates Women Awards 2013. Her array of awards over the years includes the ‘Women CEO Excellence Award’ conferred at the 9th Middle East CEO of the Year Awards; the ‘Asian Business Leadership Award’ at the Asian Business Leadership Forum Awards; the ‘Woman CEO of the Year’ at the Women in Leadership (WIL) Forum and “Business Women Award 2006 for Leadership”. She was also recognized as the 2nd most influential Arab woman in Government in the Middle East and North Africa region by Forbes Middle East in 2013 and was also rated among the 100 most powerful Arab Women earlier by CEO Middle East as well as the Asian Business Magazine. She was declared one of the most influential business women in the region by MEED magazine in 2008. She also topped Forbes Arabia’s list of the 50 most powerful Arab business women in the same year

Dr Abdullah is an industry professional with more than 20 years of experience in the healthcare industry. She is responsible for overseeing an independent regulatory authority for all healthcare providers, medical educational & research institutions and other businesses operating within the Dubai Healthcare City Free Zone. Dr Abdullah previously held the position of the Managing Director of the Science Cluster. She was responsible for managing and formulating the strategic direction of the three major companies in Dubai for the development of the knowledge based economy- namely Dubai Healthcare City Cluster and its subsidiaries, Dubai Biotechnology & Research Park- Dubiotech and Enpark, a Business Park facilitating the growth of energy and environmental businesses. Prior to that Dr Abdullah held the position of CEO of Dubai Healthcare City (DHCC). Under her leadership, DHCC rapidly gained a status as an internationally recognised location of choice for quality healthcare and an integrated centre of excellence for clinical and wellness services, medical education and research. In 2008, DHCC won the Dubai Quality award and the ‘DHCC Out-Patient Quality Standards’ were the first Middle Eastern standards to be accredited by The International Society for Quality in Healthcare (ISQUa). Prior to this, as Chief Executive Officer at the Center for Healthcare Planning and Quality (CPQ), Dr Abdullah was responsible for setting up and upholding healthcare standards within DHCC. She also played a key role in establishing CPQ into a premier regulatory body in the industry. In October 2009, Dr Abdullah received the prestigious ‘Leading Woman CEO’ Award, marking a milestone in her achievements and recognizing her strategic management and leadership acumen that significantly contributed to the healthcare cluster’s growth. She was also awarded the L’ Officiel Arab Women of the Year in 2010. She holds a bachelor’s degree in Biomedical Engineering from Marquette University in Wisconsin, USA, an MBA with an emphasis on Finance and a PhD in Strategy Management & Planning Studies from Sheffield University in the UK.

Dr. Tandon is presently engaged in investing in healthcare and healthcare/IT in USA, UAE and India. Dr. Tandon has extensive board experience. She is currently Vice Chairman of the Board of El Camino Hospital, Silicon Valley, California and Chair of its Executive Compensation Committee and Vice-Chair of its Governance and Finance Committees. Additionally she has served on 12 high tech proprietary company boards in USA. Nandini’s past investments & Board roles include,IDUN (acquired by Pfizer), U-Systems (acquired by General Electric), KAI Pharmaceuticals (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), Conforma Therapeutics (acquired by Biogen Idec), Corus Pharma (acquired by Gilead Sciences), AcordaTherapeutics (NASDAQ: ACOR), Alexza (NASDAQ: ALXA), Guava Technologies(acquired by Millipore), Ambit Biosciences, Saegis Pharmaceuticals and Cell Biosciences.Dr. Tandon has been a venture capitalist in Silicon Valley for past decade plus and was Managing Director, Lumira/MDS Capital in Palo Alto with 1.2 Billion dollar under management and before was Partner, Royal Bank of Canada’s RBC Capital Partners, in San Francisco. She is on multiple not for profit boards which are committed to global innovation, entrepreneurship and healthcare including MD Anderson Center for Entrepreneurship and PD Board, Bay Area Council Economic Institute Board, University of California, Berkeley, Center for Emerging & Neglected Diseases Board, Chair,”20/20”Vision: Investing in USA & Emerging Markets”, C21 BioVentures Board, TiE Global Board, Stanford University, School of Medicine Career Center’s Advisory Council and San Francisco-Bangalore Sister City initiative’s board and co-Chair for its SF-India focus Dr. Tandon is a strong champion for global investments in healthcare, entrepreneurship and innovation. She was delegate for President Obama’s US State Department’s Global Entrepreneurship program to Turkey, delegate for Secretary Hillary Clinton’s Women and Economy Summit, moderator for Healthcare focus of US Senator’s Congressional delegation to India, spoke at Milken Conference for Obama-Care and spoke at Clinton Global Initiative for Women in Technology, chaired investment focus for Super Return Conference in Geneva, San Francisco and Dubai, spoke at Secretary Geithner for US Department of Treasury’s symposium on Women in Finance(http://youtu.be/PH7eS4kt_FE) and recently co-chaired Healthcare delegation of Mayor of San Francisco to India. Nandini has strong operational experience as Chief Business Officer of Zyomyx Inc., Vice President of BD, Hyseq Inc. and BD Mangaer at Chiron Corp.. A White House Intern, Nandini received her Ph.D. in biochemistry, Phi Lambda Upsilon from Duke University, North Carolina and her B.A. cum laude, Sigma Xi, Phi Beta Kappa from Hollins University, Virginia.

Mr Nagori has a background working in International audit firms including Deloitte and KPMG for over 10 years. During this time he had significant experience in the audit of multinational and local companies in both India and Abu Dhabi. For the last 10 years, he has been working within the finance department of KBBO Group based in Abu Dhabi and he is currently Chief Financial Officer of KBBO Group. Mr Nagori was an Alternate Director to the Company’s previous Director, H.E. Saeed Bin Butti, from 27 June 2013 to 24 February 2014.

Mr Binay Shetty was appointed to the Board of NMC Health plc in June 2014 as a Non-Executive Director. Prior to January 2015 he was Chief Operating Officer for the Group. As COO, he oversaw operations of NMC Health’s healthcare and distribution divisions including the HR, Marketing, IT and Projects units of the organisation. From 2004-2010 he was an Executive Director of NMC with responsibility for strategic planning, governance and management of new projects. From 2006 to 2011 he was also Head of Investments for BR Shetty Pvt Investments, and from 2004 to 2006 he was Business Co-ordinator at Neopharma – Abu Dhabi’s premier pharmaceutical manufacturing company. Mr Shetty is a director of UAE Exchange, a leading global remittance and foreign exchange provider. He holds a Bachelor of Science in Business Administration with specialisations in Finance and Entrepreneurship from Boston University, Massachusetts, USA. Binay is also active in many social causes with a keen interest in the Indian social community and has been active in supporting the Special Care Centre, a school for children with special needs in Abu Dhabi.

Mr. Prasanth Manghat is the Deputy CEO and Executive Director of NMC Health. Mr. Manghat has been with the NMC group for nearly 12 years and is involved in all strategic matters at NMC Health, in addition to retaining an oversight role of the financial function of the Group. He also supports the Chief Executive Officer with planning and execution across both of NMC’s Divisions. The operational heads of both the healthcare and distribution divisions report to Mr Manghat. In April 2012, as Chief Financial Officer, Mr. Manghat spearheaded NMC Healthcare’s successful listing on the Premium Segment of the London Stock Exchange (LSE). This was a landmark transaction in many ways, being the first UAE company to list on the LSE and raising US$ 187 million in the process. Mr. Manghat has played a major role in the growth of the NMC businesses both prior to and since the IPO. Mr. Manghat was honoured with the “CFO of the Year” award – 2012 by ICAEW, Middle-East. He was also conferred with the prestigious award for “Excellence in Finance” by the Institute of Chartered Accountants of India, Abu Dhabi Chapter in Nov, 2012 and “Professional Excellence Award in the Healthcare Sector” by ICAI UAE (Dubai) Chapter in May 2013. Prior to joining NMC, Mr. Manghat has worked as Credit and Operations Head with Kotak Mahindra Finance, one of the leading non-banking financial institutions in India. A Fellow member of the Institute of Chartered Accountants of India (FCA), Bachelor of Science (1995), MG University, Kerala, India, CIA, ACCA from UK (2004) and pursuing CA (Institute of Chartered Accountants of England and Wales), he has 14 years of experience in management of treasury and banking functions, corporate finance, accounting and financial reporting activities.